Understanding patient and partner needs deeply and then developing products to meet those needs is central to our purpose. Over the last three decades, we have transformedour company—from a maker of Active Ingredients to a global, patient-centric company with a global footprint in over 20 countries. We have successfully developed and marketed range of products, many of which are leaders in their respective markets.
Here are some of the most prominent therapies that we focus on*:
Cancer is a disease that requires specialized treatment and care at every stage. Having understood patient and partner needs deeply, we have developed a broad range of high-quality cancer care medications. Across the spectrum of cytotoxics, targeted therapies and supportive care, our range is designed to effectively combat cancer and the side effects associated with the therapy.
Oncology is also the field where we’ve successfully demonstrated our cutting-edge research and development capabilities. Among our numerous achievements is the development of the world’s first recombinant human GCSF biosimilar protein, the world’s first bio-similar therapeutic monoclonal antibody and the single source pegfilgrastim.
To know more about this Click here
Heartburn is a common symptom of Gastroesophageal reflux disease, a widespread gastrointestinal disorder that is becoming increasingly prevalent worldwide.
Dr Reddy’s has developed a broad portfolio of acid suppressive medications to address this widely prevalent and debilitating disease. Our portfolio consists of some of the leading brands, including our flagship brand OMEZ. In addition, Dr. Reddy’s has a varied portfolio that addresses various other gastrointestinal disorders such as irritable bowel, diarrhea and constipation, both in adults and children. We have recently ventured into Hepatology segment to address the patient needs of Hepatitis B and Hepatitis C, providing affordable medications to more people.
Changing lifestyles and dietary patterns are causing an unprecedented surge in the incidence of cardiovascular diseases. Hypertension is probably the most prevalent of these. In keeping with changing patient needs, Dr Reddy’s has developed a wide and varied portfolio of anti-hypertensive medicines to bring good health to the millions affected by this condition. Our portfolio consists of a number of successful products including Amlodipine, Amlodipine+Atenolol combination, ACE inhibitors like Enalapril as well as angiotensin receptor blockers (ARBs) like Telmisartan.
Since patient compliance is crucial in controlling hypertension, our development focus has been on improving convenience and comfort. This led us to create a number of innovations like monthly packs of our Atorvastatin and Telmisartan products in India, for example.
Along with hypertension, diabetes is another rapidly growing lifestyle health condition, the world over. Dr. Reddy’s has a number of established products like Metformin, Glimepride, Glicazide and their combinations in its portfolio, to ensure good health to diabetics.
Many of our development efforts focus on initiatives to help improve patient compliance. For example, we successfully developed a patient-friendly dosage form of Metformin that was easily swallowed, and helped the patient stick to the prescribed treatment regimen.
Dr Reddy’s has proven expertise to develop solutions for health conditions such as Seborrheic Dermatitis, Psoriasis, Corticosteroid-responsive Dermatoses, various types of Dermatitis, Actinic Keratosis, Rosacea, Warts and Acne. In fact, some of our over-the-counter (OTC) products in the area of trichology and hair regrowth are leading brands in their own right.
Our solutions go far beyond the pill. We have successfully developed and deployed patient-programs that help patient compliance, especially in conditions like Acne.
Dr. Reddy’s has a number of established products – both generic and branded generic – that address a wide range of pain conditions. Products such as Nise, our brand of Nimesulide, is one of the top 300 brands in the Indian pharmaceutical market, for instance. Apart from Nimesulide, we have a number of other products including Ketorolac and Hyaluronic acid that form a significant part of our portfolio. Our development effort focuses on creating newer combinations as well as exploring new delivery mechanisms to improve patient comfort, convenience and efficacy.